Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| KetoNaph | Experimental | KetoNaph (ketotifen fumarate 0.025%, naphazoline HCl 0.05%) ophthalmic solution |
|
| Naphazoline | Active Comparator | Naphazoline HCl 0.05% ophthalmic solution |
|
| Ketotifen | Active Comparator | Ketotifen fumarate 0.025% ophthalmic solution |
|
| Vehicle | Placebo Comparator | Vehicle of KetoNaph ophthalmic solution |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketotifen/naphazoline | Drug | One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Ocular Itching | Ocular itching was evaluated by the participant at 3, 5, and 7 minutes post challenge. Assessments were made using a 0-4 numerical analog scale, allowing 0.5-unit increments (but disallowing 0.25-unit increments), where: 0.0 = None and 4.0 = Incapacitating itch with an irresistible urge to rub. | 3, 5, and 7 minutes post challenge at 14 days |
| Conjunctival Hyperemia | Conjunctival hyperemia was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were completed using a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0 = None and 4.0 = Extremely severe. | 7, 15, and 20 minutes post challenge at 14 days |
| Measure | Description | Time Frame |
|---|---|---|
| Ciliary Redness | Ciliary hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using a 0-4 scale, allowing 0.5- unit increments, with 0.0 = None and 4.0 = Extremely severe. | 7, 15, and 20 minutes post challenge at 14 days |
| Episcleral Redness |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ophthalmic Research Consultants, Inc. | North Andover | Massachusetts | 01845 | United States |
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | KetoNaph | KetoNaph (ketotifen fumarate 0.025%, naphazoline HCl 0.05%) ophthalmic solution Ketotifen/naphazoline: One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4. |
| FG001 | Ketotifen | Ketotifen fumarate 0.025% ophthalmic solution Ketotifen: One drop of Ketotifen in study eye at visit 3 and visit 4. |
| FG002 | Naphazoline | Naphazoline HCl 0.05% ophthalmic solution Naphazoline: One drop of naphazoline in study eye at vist 3 and visit 4. |
| FG003 | Vehicle | Vehicle of KetoNaph ophthalmic solution Vehicle: One drop of vehicle in study eye at visit 3 and visit 4. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | KetoNaph | KetoNaph (ketotifen fumarate 0.025%, naphazoline HCl 0.05%) ophthalmic solution Ketotifen/naphazoline: One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4. |
| BG001 | Ketotifen |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Ocular Itching | Ocular itching was evaluated by the participant at 3, 5, and 7 minutes post challenge. Assessments were made using a 0-4 numerical analog scale, allowing 0.5-unit increments (but disallowing 0.25-unit increments), where: 0.0 = None and 4.0 = Incapacitating itch with an irresistible urge to rub. | Posted | Mean | Standard Deviation | score on a scale | 3, 5, and 7 minutes post challenge at 14 days | eyes | eyes |
|
14 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | KetoNaph | KetoNaph (ketotifen fumarate 0.025%, naphazoline HCl 0.05%) ophthalmic solution Ketotifen/naphazoline: One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Bausch Health | 908-300-9920 | susan.harris@bauschhealth.com |
Not provided
| ID | Term |
|---|---|
| D003233 | Conjunctivitis, Allergic |
| ID | Term |
|---|---|
| D003231 | Conjunctivitis |
| D003229 | Conjunctival Diseases |
| D005128 | Eye Diseases |
| D006969 | Hypersensitivity, Immediate |
Not provided
Not provided
| ID | Term |
|---|---|
| D007665 | Ketotifen |
| D009278 | Naphazoline |
| ID | Term |
|---|---|
| D013876 | Thiophenes |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Ketotifen | Drug | One drop of Ketotifen in study eye at visit 3 and visit 4. |
|
| Naphazoline | Drug | One drop of naphazoline in study eye at vist 3 and visit 4. |
|
| Vehicle | Drug | One drop of vehicle in study eye at visit 3 and visit 4. |
|
Episcleral hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using a 0-4 scale, allowing 0.5- unit increments, with 0.0 = None and 4.0 = Extremely severe. |
| 7, 15, and 20 minutes post challenge at 14 days |
| Chemosis | Chemosis was evaluated by the Investigator at 7, 15, and 20 minutes post challenge on a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0 = None and 4.0 = Extremely severe. | 7, 15, and 20 minutes post challenge at 14 days |
| Eyelid Swelling | Lid swelling was evaluated by the subject at 7, 15, and 20 minutes post challenge on a 0- 3 numerical analog scale, with 0.5-unit increments disallowed, where: 0.0 = None and 3.0 = Severe. | 7, 15, and 20 minutes post challenge at 14 days |
| Percentage of Eyes With Tearing | Tearing was evaluated by the subject at 7, 15, and 20 minutes post challenge (absent or present). Tearing was recorded as either absent or present. | 7, 15, and 20 minutes post challenge at 14 days |
| Percentage of Eyes With Ocular Mucus Drainage | Ocular mucous discharge was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Mucous discharged was recorded as either absent or present. | 7, 15, and 20 minutes post challenge at 14 days |
Ketotifen fumarate 0.025% ophthalmic solution Ketotifen: One drop of Ketotifen in study eye at visit 3 and visit 4.
| BG002 | Naphazoline | Naphazoline HCl 0.05% ophthalmic solution Naphazoline: One drop of naphazoline in study eye at vist 3 and visit 4. |
| BG003 | Vehicle | Vehicle of KetoNaph ophthalmic solution Vehicle: One drop of vehicle in study eye at visit 3 and visit 4. |
| BG004 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG002 | Naphazoline | Naphazoline HCl 0.05% ophthalmic solution Naphazoline: One drop of naphazoline in study eye at vist 3 and visit 4. |
| OG003 | Vehicle | Vehicle of KetoNaph ophthalmic solution Vehicle: One drop of vehicle in study eye at visit 3 and visit 4. |
|
|
| Primary | Conjunctival Hyperemia | Conjunctival hyperemia was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were completed using a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0 = None and 4.0 = Extremely severe. | Posted | Mean | Standard Deviation | units on a scale | 7, 15, and 20 minutes post challenge at 14 days | eyes | eyes |
|
|
|
| Secondary | Ciliary Redness | Ciliary hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using a 0-4 scale, allowing 0.5- unit increments, with 0.0 = None and 4.0 = Extremely severe. | This outcome measure was not assessed for the Vehicle group. | Posted | Mean | Standard Deviation | units on a scale | 7, 15, and 20 minutes post challenge at 14 days | eyes | eyes |
|
|
|
| Secondary | Episcleral Redness | Episcleral hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using a 0-4 scale, allowing 0.5- unit increments, with 0.0 = None and 4.0 = Extremely severe. | This outcome measure was not assessed for the Vehicle group. | Posted | Mean | Standard Deviation | score on a scale | 7, 15, and 20 minutes post challenge at 14 days | eyes | eyes |
|
|
|
| Secondary | Chemosis | Chemosis was evaluated by the Investigator at 7, 15, and 20 minutes post challenge on a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0 = None and 4.0 = Extremely severe. | This outcome measure was not assessed for the Vehicle group. | Posted | Mean | Standard Deviation | score on a scale | 7, 15, and 20 minutes post challenge at 14 days | eyes | eyes |
|
|
|
| Secondary | Eyelid Swelling | Lid swelling was evaluated by the subject at 7, 15, and 20 minutes post challenge on a 0- 3 numerical analog scale, with 0.5-unit increments disallowed, where: 0.0 = None and 3.0 = Severe. | This outcome measure was not assessed for the Vehicle group. | Posted | Mean | Standard Deviation | score on a scale | 7, 15, and 20 minutes post challenge at 14 days | eyes | eyes |
|
|
|
| Secondary | Percentage of Eyes With Tearing | Tearing was evaluated by the subject at 7, 15, and 20 minutes post challenge (absent or present). Tearing was recorded as either absent or present. | This outcome measure was not assessed for the Vehicle group. | Posted | Count of Units | eyes | 7, 15, and 20 minutes post challenge at 14 days | eyes | eyes |
|
|
|
| Secondary | Percentage of Eyes With Ocular Mucus Drainage | Ocular mucous discharge was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Mucous discharged was recorded as either absent or present. | This outcome measure was not assessed for the Vehicle group. | Posted | Count of Units | eyes | 7, 15, and 20 minutes post challenge at 14 days | eyes | eyes |
|
|
|
| 0 |
| 36 |
| 0 |
| 36 |
| EG001 | Ketotifen | Ketotifen fumarate 0.025% ophthalmic solution Ketotifen: One drop of Ketotifen in study eye at visit 3 and visit 4. | 0 | 36 | 0 | 36 |
| EG002 | Naphazoline | Naphazoline HCl 0.05% ophthalmic solution Naphazoline: One drop of naphazoline in study eye at vist 3 and visit 4. | 0 | 35 | 0 | 35 |
| EG003 | Vehicle | Vehicle of KetoNaph ophthalmic solution Vehicle: One drop of vehicle in study eye at visit 3 and visit 4. | 0 | 37 | 0 | 37 |
Contact sponsor directly for details.
| D006967 |
| Hypersensitivity |
| D007154 | Immune System Diseases |
| D006573 |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D007093 | Imidazoles |
| D001393 | Azoles |
| eyes |
|
| 15 minutes post-challenge |
|
| 20 minutes post-challenge |
|
| eyes |
|
|
| 20 minutes post-challenge |
|
| eyes |
|
|
| 20 minutes post-challenge |
|
| eyes |
|
|
| 20 minutes post-challenge |
|
| eyes |
|
|
| 20 minutes post-challenge |
|
| eyes |
|
|
| 20 minutes post-challenge |
|
| eyes |
|
|
| 20 minutes post-challenge |
|